Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Priority Medicines

- PMLiVE

AAA’s orphan drug Lutathera wins EU green light

The first-in-class drug treats adults with GEP-NET

- PMLiVE

EMA sets aside £32m for temporary staff to help with Brexit move

As agency warns current tender system needs to be updated

EU flag

Europe’s cancer drug regulation is ‘broken’, claims study

Suggests EMA oncology approvals could lead to wasted funds and patient harm

- PMLiVE

EMA faces ‘permanent damage’ if forced to go to an unpopular city

Warns eight candidate cities wouldn't retain minimum staff numbers it needs

- PMLiVE

Takeda can’t sway NICE on oral myeloma therapy Ninlaro

Drug not recommended for NHS use in England and Wales

- PMLiVE

UK life sciences sector sets out its post-Brexit growth proposals

Review helmed by Sir John Bell outlines a wide-ranging strategy

UK Life Sciences Strategy - one year on

EMA starts firming up its stance on personalised medicines

But draft guidelines won't be ready much before 2019

- PMLiVE

How to keep your name development on schedule after the recent EMA NRG announcement

Three key action points

- PMLiVE

Most of the EU would like to host the EMA

Nineteen member states will compete to host the agency when it leaves the UK

- PMLiVE

Amgen aspires to new Kyprolis label in the US and Europe

Appeals to regulators to add survival data to multiple myeloma drug's labelling

- PMLiVE

UK pharma launches legal challenge to NICE plans

Applies for judicial review of budget impact test

- PMLiVE

Europe vs the US: New drug product approvals

As US approvals rates in the US drop,  the EU is not currently showing a similar trend

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links